10x Genomics, INC 10-Q quarterly reports

10x Genomics, Inc. reported a significantly reduced net loss for Q3 2025 and the nine months ended September 30, 2025, driven by substantial license and royalty revenue from patent settlements and effective cost reduction strategies, alongside a strategic acquisition.

10x Genomics reported a net income of $34.5 million in Q2 2025, driven by significant patent litigation settlements, and announced the acquisition of Scale Biosciences.

10x Genomics' Q1 2025 revenue shows a mixed performance with a decrease in product sales offset by licensing revenue from a settlement with Vizgen.

10x Genomics' Q3 2024 results show a slight revenue decrease and a reduced net loss compared to the same period last year, while the company continues to navigate complex patent litigation.

10x Genomics' second quarter results show a slight revenue increase but a continued net loss, alongside ongoing legal proceedings and strategic shifts.

10x Genomics saw a 5% increase in revenue year-over-year in Q1 2024, driven by strong growth in spatial instrument sales, though consumables revenue declined slightly.